Abstract
Since the introduction of glucose-insulin-potassium therapy for acute myocardial infarction 20 years ago, there have been many attempts to determine the efficacy of this treatment. Some trials have shown that this therapy is antiarrhythmic and others have found no benefit. In this study we demonstrate that concentrations of glucose found to be antiarrhythmic in recent clinical trials exert favorable effects on resting membrane potential, overshoot, and rising velocity in hypoxic canine heart cells. The refractory period, shortened by hypoxia, is also significantly lengthened by extra glucose. All of these single-cell effects are potentially antiarrhythmic and may explain the effectiveness of this therapy.
Collapse